Search

RU-2861617-C2 - PHARMACEUTICAL COMPOSITION COMPRISING RIBOSE AND AMINO ACIDS

RU2861617C2RU 2861617 C2RU2861617 C2RU 2861617C2RU-2861617-C2

Abstract

FIELD: medicine. SUBSTANCE: invention relates to the field of therapy of bacterial urinary tract infections and concerns the use of an oral composition comprising ribose and amino acids. There is provided the use of an oral composition comprising ribose and the amino acids glycine, alanine and glutamine in an aqueous solution, for treating a bacterial urinary tract infection in a patient who is simultaneously receiving treatment with an antibiotic or a sulphonamide, wherein the relative amounts of the amino acids glycine:alanine:glutamine in the composition are 1:8-12:10-15 and wherein the relative amounts of ribose and the amino acids glycine, alanine and glutamine (ribose:amino acids) in the composition are 1:0.8-2.0. The administration of the composition provides a daily dose of ribose of from 1200 to 2400 mg, glycine of from 60 to 150 mg, alanine of from 600 to 1500 mg, glutamine of from 800 to 1800 mg. EFFECT: ability to increase the effectiveness of treating bacterial infections by reducing bacterial resistance to antibiotics. 11 cl, 17 dwg, 5 tbl

Inventors

  • SCHMIED, ARNOLD

Dates

Publication Date
20260506
Application Date
20221102
Priority Date
20211220

Claims (11)

  1. 1. The use of an oral composition comprising ribose and the amino acids glycine, alanine and glutamine in an aqueous solution for the treatment of a bacterial urinary tract infection in a patient who is simultaneously receiving treatment with an antibiotic or a sulfonamide, wherein the relative amounts of the amino acids glycine:alanine:glutamine in the composition are 1:8-12:10-15; and wherein the relative amounts of ribose and the amino acids glycine, alanine and glutamine (ribose:amino acids) in the composition are 1:0.8-2.0, wherein the administration of the composition provides a daily dose of ribose from 1200 to 2400 mg, glycine from 60 to 150 mg, alanine from 600 to 1500 mg, glutamine from 800 to 1800 mg.
  2. 2. The use according to claim 1, wherein the ribose is D-ribose, and/or wherein the alanine is racemic (D/L)-alanine, and/or wherein the glutamine is L-glutamine.
  3. 3. The use according to any of the preceding claims, wherein the concentration of ribose in the aqueous solution of the composition is from 30 to 40 g/l, and/or the concentration of glycine in the aqueous solution of the composition is from 1.5 to 2.5 g/l, and/or the concentration of alanine in the aqueous solution of the composition is from 15 to 25 g/l, and/or the concentration of glutamine in the aqueous solution of the composition is from 20 to 30 g/l.
  4. 4. Use according to any of the preceding paragraphs, wherein the volume of the aqueous solution of the composition is 10-30 ml.
  5. 5. The use according to any of the preceding claims, wherein the composition is administered to the patient two or three times a day, and/or wherein the composition is administered to the patient daily for a period of one to three weeks.
  6. 6. The use according to any of the preceding claims, wherein the antibiotic co-administered to the patient may be a penicillin, in particular ampicillin, a cephalosporin antibiotic such as cefazolin, a fluoroquinolone antibiotic such as ciprofloxacin.
  7. 7. The use according to any of the preceding claims, wherein the sulfonamide co-administered to the patient is sulfamethoxazole.
  8. 8. The use according to any of the preceding claims, wherein the sulfonamide is administered to the patient in combination with trimethoprim.
  9. 9. The use according to any of the preceding claims, where the infection is caused by bacterial strains that are multiply resistant to antibiotics, in particular Escherichia Coli or Klebsiella Pneumonia that are multiply resistant to antibiotics.
  10. 10. The use according to any of the preceding claims, wherein the composition is administered simultaneously with each or every second administration of the antibiotic.
  11. 11. Use according to any one of claims 1-9, wherein the composition is administered at least half an hour and no more than five hours before each or every second administration of the antibiotic.

Description

The invention relates to a composition for use in a method for treating a bacterial infection selected from a bacterial urinary tract infection, a bacterial respiratory tract infection, a bacterial soft tissue infection, and a bacterial bone infection in a patient. Urinary tract infections are among the most common bacterial diseases worldwide. The prevalence of infection in the general population is 0.7%. The prevalence of healthcare-associated UTIs among healthcare-associated infections is 12.9%, 19.6%, and 24% in the United States, Europe, and developing countries, respectively. In urology departments, the prevalence is 5.1%. Urinary tract infections are frequently caused by both gram-negative and gram-positive bacteria, often Escherichia coli and Klebsiella pneumoniae. High recurrence rates and increasing antimicrobial resistance among uropathogens threaten to significantly increase the burden of these infections. The invention provides a new method for treating a bacterial infection selected from a bacterial urinary tract infection, a bacterial respiratory tract infection, a bacterial soft tissue infection, and a bacterial bone infection in a patient. In particular, the invention provides a composition for use in a method for treating a bacterial infection selected from a bacterial urinary tract infection, a bacterial respiratory tract infection, a bacterial soft tissue infection, and a bacterial bone infection in a patient, wherein the composition comprises ribose and the amino acids glycine, alanine, and glutamine in an aqueous solution. The method comprises orally administering the composition to the patient who is simultaneously receiving antibiotic treatment. Preferably, the infection being treated is a bacterial urinary tract infection. Ribose is preferably D-ribose. Alanine is preferably racemic (D/L)-alanine. Glutamine is preferably L-glutamine. The concentration of ribose in the aqueous solution of the composition is preferably from 30 to 40 g/l. The concentration of glycine in the aqueous solution of the composition is preferably from 1.5 to 2.5 g/l. The concentration of alanine in the aqueous solution of the composition is preferably from 15 to 25 g/l. The concentration of glutamine in the aqueous solution of the composition is preferably from 20 to 30 g/l. The relative concentrations of amino acids in the aqueous solution of the composition are preferably 1:8-12:10-15 (glycine:alanine:glutamine). The relative concentrations of ribose and the amino acids glycine, alanine and glutamine in the aqueous solution of the composition are preferably 1:0.8-2.0 (ribose:amino acids). The volume of the aqueous solution of the composition is preferably 5-50 ml, preferably 10-30 ml. In a preferred embodiment, the composition is administered to the patient two or three times daily. Twice daily administration may be most preferred. In embodiments of the invention, the composition may be administered to the patient daily for a period of one to three weeks, preferably one to two weeks. The amount of ribose administered to the patient per day is preferably from 1200 to 2400 mg. The amount of glycine administered to the patient per day is preferably from 60 to 150 mg. The amount of alanine administered to the patient per day is preferably from 600 to 1500 mg. The amount of glutamine administered to the patient per day is preferably from 800 to 1800 mg. The relative amounts of amino acids administered to the patient are preferably 1:8-12:10-15 (glycine:alanine:glutamine). The relative amounts of ribose and the amino acids glycine, alanine and glutamine administered to the patient are preferably 1:0.8-2.0 (ribose:amino acids). The patient is preferably a human patient. In particular, the human patient may be an adult over 18 years of age. In one embodiment, the composition can be used to treat infections caused by a bacterial strain that is multiply resistant to antibiotics, in particular bacterial strains of Escherichia coli or Klebsiella pneumoniae that are multiply resistant to antibiotics. It has previously been suggested that a composition comprising ribose, glycine, alanine, and glutamine may have a beneficial effect in the treatment of infections caused by multiply resistant bacteria, in DE 10 2011 105 594 B4. The method typically involves treating the patient with an antibiotic in addition to co-treating the patient with a composition of the invention. The composition of the invention is designed to enhance the effect of the antibiotic. In one embodiment, the composition of the invention is administered simultaneously with each or every other antibiotic administration. In another embodiment, the composition of the invention is administered at least half an hour and no more than five hours before each or every other antibiotic administration. This is because the composition may increase the sensitivity of bacteria to antibiotics and should be allowed to act on the bacteria before the antibiotics are admini